| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| lidocaine hydrochloride | Injection, concentrated | 100 mg/mL | Anticipated | Available | Manufacturing | 9/01/2026 |
| trandolapril | Capsule | 4 mg | Current | Limited Availability | Manufacturing | 9/01/2026 |
| isoniazid | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 160 mg~12.5 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| temozolomide | Capsule, hard | 20 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| simvastatin~ezetimibe | Tablet | 40 mg~10 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| clindamycin hydrochloride | Capsule, hard | 162.87 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| clindamycin hydrochloride | Capsule, hard | 162.87 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| dulaglutide | Injection, solution | 1.5 mg | Resolved | Available | Manufacturing | 9/01/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 9/01/2026 |
| tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| ambrisentan | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| ambrisentan | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 9/01/2026 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~40 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| bimatoprost | Eye Drops | .3 mg/mL | Current | Limited Availability | Manufacturing | 9/01/2026 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| paroxetine hydrochloride | Tablet, film coated | 22.22 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| Adalimumab | Injection, solution | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 9/01/2026 |
| gliclazide | Tablet, uncoated | 80 mg | Anticipated | Available | Manufacturing | 9/01/2026 |
| estradiol | Drug delivery system, transdermal | .585 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| lamotrigine | Tablet, chewable | 100 mg | Resolved | Available | Manufacturing | 9/01/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| nitrofurantoin | Capsule, hard | 100 mg | Resolved | Available | Unexpected increase in consumer demand | 9/01/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| mupirocin | Ointment | 20 mg/g | Resolved | Available | Manufacturing | 9/01/2026 |
| levodopa~carbidopa monohydrate | Tablet, uncoated | 100 mg~26.9 mg | Current | Limited Availability | Manufacturing | 9/01/2026 |
| pioglitazone hydrochloride | Tablet, uncoated | 16.53 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| pioglitazone hydrochloride | Tablet, uncoated | 33.06 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| pioglitazone hydrochloride | Tablet, uncoated | 49.59 mg | Current | Unavailable | Manufacturing | 9/01/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 9/01/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Manufacturing | 9/01/2026 |
| rifampicin | Oral Liquid | 20 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 8/01/2026 |
| baclofen | Tablet, uncoated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 8/01/2026 |
| trandolapril | Capsule | 2 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 8/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 555 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| nortriptyline | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 8/01/2026 |
| lamotrigine | Tablet, chewable | 100 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| finasteride | Tablet, film coated | 1 mg | Anticipated | Available | Unexpected increase in consumer demand | 8/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 8/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 30.768 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 8/01/2026 |
| bisoprolol fumarate | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| bisoprolol fumarate | Tablet | 10 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| levetiracetam | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| rocuronium bromide | Injection, solution | 50 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| exemestane | Tablet, sugar coated | 25 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| mirtazapine | Tablet, orally disintegrating | 15 mg | Anticipated | Available | Manufacturing | 8/01/2026 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Anticipated | Available | Manufacturing | 8/01/2026 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| enalapril maleate | Tablet | 5 mg | Current | Unavailable | Manufacturing | 8/01/2026 |
| enalapril maleate | Tablet | 5 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| quetiapine fumarate | Tablet, modified release | 230.26 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| GluureaLys(ahx)hbedCC | Injection, powder for | 25 microgram | Resolved | Available | Manufacturing | 8/01/2026 |
| GluureaLys(ahx)hbedCC | Injection, powder for | 25 microgram | Resolved | Available | Manufacturing | 8/01/2026 |
| mitomycin | Injection, powder for | 20 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| isoprenaline hydrochloride | Injection, solution | 1 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 8/01/2026 |
| diltiazem hydrochloride | Capsule, modified release | 180 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| diltiazem hydrochloride | Capsule, modified release | 360 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 582.21 mg | Current | Limited Availability | Manufacturing | 8/01/2026 |
| nizatidine | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 8/01/2026 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 10.25 mg~8 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 8/01/2026 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 20.51 mg~16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 8/01/2026 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 30.76 mg~24 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 8/01/2026 |
| bethanechol chloride | Tablet, uncoated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 7/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 7/01/2026 |
| cyproterone acetate | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 7/01/2026 |
| paclitaxel | Injection, powder for | 100 mg | Anticipated | Available | Manufacturing | 7/01/2026 |
| cabazitaxel | Injection, concentrated | 60 mg | Current | Limited Availability | Manufacturing | 7/01/2026 |
| rimegepant sulfate | Tablet, orally disintegrating | 85.65 mg | Anticipated | Available | Manufacturing | 7/01/2026 |
| stannous chloride dihydrate | Injection, powder for | 19.2 microgram/mL | Current | Unavailable | Manufacturing | 7/01/2026 |
| ropivacaine hydrochloride | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 7/01/2026 |
| desferrioxamine mesilate | Injection, powder for | 2 g | Current | Limited Availability | Manufacturing | 7/01/2026 |
| etoposide phosphate | Injection, powder for | 1136 mg | Current | Limited Availability | Manufacturing | 7/01/2026 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Resolved | Available | Unexpected increase in consumer demand | 6/01/2026 |
| diclofenac potassium | Oral Liquid, powder for | 50 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 6/01/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 6/01/2026 |
| calcium folinate hydrate | Tablet, uncoated | 18.6 mg | Anticipated | Available | Unexpected increase in consumer demand | 6/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 6/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 6/01/2026 |
| montelukast sodium | Tablet | 10.4 mg | Anticipated | Available | Commercial Changes / Commercial viability | 6/01/2026 |
| pemetrexed disodium | Injection, powder for | 1102.9 mg | Current | Unavailable | Manufacturing | 6/01/2026 |
| Pegvisomant | Injection, powder for | 10 mg | Resolved | Available | Manufacturing | 6/01/2026 |
| topotecan hydrochloride | Injection, concentrated | 4.346 mg | Current | Limited Availability | Unexpected increase in consumer demand | 6/01/2026 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Current | Unavailable | Manufacturing | 6/01/2026 |
| live varicella vaccine | Injection, powder for | 2700 PFU/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 5/01/2026 |
| risperidone | Tablet | 1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/01/2026 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 5/01/2026 |
| iopromide | Injection, solution | 498.72 mg/mL | Resolved | Available | Manufacturing | 5/01/2026 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 5/01/2026 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 5/01/2026 |
| pemetrexed disodium | Injection, powder for | 551.4 mg | Current | Limited Availability | Manufacturing | 5/01/2026 |
| linezolid | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 5/01/2026 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 40 mg~12.5 mg | Current | Unavailable | Manufacturing | 5/01/2026 |
| sildenafil citrate | Tablet, film coated | 70.24 mg | Current | Unavailable | Commercial Changes / Commercial viability | 5/01/2026 |
| prilocaine hydrochloride | Injection, solution | 100 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 5/01/2026 |
| cefalexin monohydrate | Capsule, hard | 250 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 5/01/2026 |
2026年1月12日